Pasar al contenido principal

DESARROLLO TECNICO DE UN EQUIPO PARA DETERMINAR EN EL PUNTO DE ATENCION LA IMMUNOSUPERSION DE PACIENTES CRITICOS CON SEPSIS BASADO EN LA ACTIVIDAD DEL INFLAMASOMA NLRP3

DTS21/00080

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Desarrollo Tecnológico en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
Centro realización INSTITUTO MURCIANO DE INVESTIGACION BIOSANITARIA (IMIB)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure

  • Malhotra, Sunny|||0000-0003-1112-7739
  • Hurtado-Navarro, Laura|||0000-0002-9544-6042
  • Pappolla, Agustin|||0000-0001-6364-9497
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Río, Jordi|||0000-0003-4546-7627
  • Montalban, Xavier|||0000-0002-0098-9918
  • Pelegrín, Pablo|||0000-0002-9688-1804
  • Comabella López, Manuel|||0000-0002-2373-6657
Inflammasomes are involved in the pathogenesis of different neuroimmune and neurodegenerative diseases, including multiple sclerosis (MS). In a previous study by our group, the nucleotide-binding oligomerization domain, leucine-rich repeat receptor and pyrin-domain-containing 3 (NLRP3) inflammasome was reported to be associated with the response to interferon-beta in MS. Based on recent data showing the potential for the oral therapy fingolimod to inhibit NLRP3 inflammasome activation, here we investigated whether fingolimod could also be implicated in the response to this therapy in patients with MS. NLRP3 gene expression levels were measured by real-time PCR in peripheral blood mononuclear cells at baseline and after 3, 6, and 12 months in a cohort of patients with MS treated with fingolimod (N = 23), dimethyl fumarate (N = 21), and teriflunomide (N = 21) and classified into responders and nonresponders to the treatment according to clinical and radiologic criteria. In a subgroup of fingolimod responders and nonresponders, the percentage of monocytes with an oligomer of ASC was determined by flow cytometry, and the levels of interleukin (IL)-1β, IL-18, IL-6, tumor necrosis factor (TNF)α, and galectin-3 were quantified by ELISA. NLPR3 expression levels were significantly increased in fingolimod nonresponders after 3 (p = 0.03) and 6 months (p = 0.008) of treatment compared with the baseline but remained similar in responders at all time points. These changes were not observed in nonresponders to the other oral therapies tested. The formation of an oligomer of ASC in monocytes after lipopolysaccharide and adenosine 5'-triphosphate stimulation was significantly decreased in responders (p = 0.006) but increased in nonresponders (p = 0.0003) after 6 months of fingolimod treatment compared with the baseline. Proinflammatory cytokine release from stimulated peripheral blood mononuclear cells was comparable between responders and nonresponders, but galectin-3 levels on cell supernatants, as a marker of cell damage, were significantly increased in fingolimod nonresponders (p = 0.02). The differential effect of fingolimod on the formation of an inflammasome-triggered ASC oligomer in monocytes between responders and nonresponders could be used as a response biomarker after 6 months of fingolimod treatment and suggests that fingolimod may exert their beneficial effects by reducing inflammasome signaling in a subset of patients with MS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

  • Hurtado-Navarro, Laura|||0000-0002-9544-6042
  • Cuenca-Zamora, Ernesto José
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Such, Esperanza|||0000-0001-6892-403X
  • Soler-Espejo, Eva
  • Martínez-Banaclocha, Helios
  • Hernández Bermúdez, J.
  • Marco-Ayala, Javier
  • Martínez-Alarcón, Laura
  • Linares-Latorre, Lola
  • Garcia-Avila, Sara|||0000-0002-9293-2029
  • Amat, Paula
  • González, Teresa
  • Arnan, Montserrat
  • Pomares-Marín, Helena
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Chen-Liang, Tzu Hua
  • Herranz, María T.
  • García-Palenciano, Carlos
  • Morales, María Luz
  • Jerez, Andrés|||0000-0002-2079-6638
  • Lozano, María L.
  • Teruel-Montoya, Raúl
  • Pelegrín, Pablo|||0000-0002-9688-1804
  • Ferrer-Marín, Francisca|||0000-0002-9520-3243
Chronic myelomonocytic leukemia (CMML) is frequently associated with mutations in the rat sarcoma gene (RAS), leading to worse prognosis. RAS mutations result in active RAS-GTP proteins, favoring myeloid cell proliferation and survival and inducing the NLRP3 inflammasome together with the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which promote caspase-1 activation and interleukin (IL)-1β release. Here, we report, in a cohort of CMML patients with mutations in KRAS, a constitutive activation of the NLRP3 inflammasome in monocytes, evidenced by ASC oligomerization and IL-1β release, as well as a specific inflammatory cytokine signature. Treatment of a CMML patient with a KRAS mutation using the IL-1 receptor blocker anakinra inhibits NLRP3 inflammasome activation, reduces monocyte count, and improves the patient's clinical status, enabling a stem cell transplant. This reveals a basal inflammasome activation in RAS-mutated CMML patients and suggests potential therapeutic applications of NLRP3 and IL-1 blockers.